nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.
Company profile
Ticker
NKTX
Exchange
Website
CEO
Paul J. Hastings
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
474515206
NKTX stock data
Latest filings (excl ownership)
8-K
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
13 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K
Other Events
28 Mar 24
424B5
Prospectus supplement for primary offering
25 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.92 mm | 10.84 mm | 9.50 mm | 7.83 mm |
Cash used (since last report) | n/a | n/a | 30.98 mm | 30.76 mm | 26.96 mm | 22.20 mm |
Cash remaining | n/a | n/a | 222.04 mm | 222.27 mm | 226.07 mm | 230.82 mm |
Runway (months of cash) | n/a | n/a | 20.3 | 20.5 | 23.8 | 29.5 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 118 |
Opened positions | 61 |
Closed positions | 13 |
Increased positions | 22 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 659.47 bn |
Total shares | 81.89 mm |
Total puts | 114.20 k |
Total calls | 145.00 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 10.81 mm | $116.80 bn |
Boxer Capital | 5.61 mm | $60.62 bn |
Deerfield Management | 5.19 mm | $56.15 bn |
Adage Capital Partners GP, L.L.C. | 3.80 mm | $41.08 bn |
Samsara BioCapital | 3.77 mm | $41.77 mm |
Samsara BioCapital | 3.77 mm | $40.73 bn |
NEA Management | 3.57 mm | $38.58 bn |
New Enterprise Associates 15 | 3.57 mm | $39.56 mm |
Flynn James E | 3.40 mm | $10.68 mm |
SR One Capital Management | 3.33 mm | $36.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jun 24 | Ralph Brandenberger | Common Stock | Sell | Dispose S | No | No | 5.6 | 229 | 1.28 k | 79,743 |
18 Jun 24 | David Shook | Common Stock | Sell | Dispose S | No | No | 5.6 | 456 | 2.55 k | 116,524 |
18 Jun 24 | Alicia J. Hager | Common Stock | Sell | Dispose S | No | No | 5.6 | 727 | 4.07 k | 107,215 |
18 Jun 24 | Hastings Paul J | Common Stock | Sell | Dispose S | No | No | 5.6 | 1,770 | 9.91 k | 240,737 |
18 Jun 24 | James Trager | Common Stock | Sell | Dispose S | No | No | 5.6 | 456 | 2.55 k | 150,959 |
News
HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $23
13 May 24
Needham Maintains Buy on Nkarta, Lowers Price Target to $13
13 May 24
Canaccord Genuity Maintains Buy on Nkarta, Lowers Price Target to $15
10 May 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Apr 24
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
11 Apr 24
Press releases
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
13 Jun 24
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
15 May 24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
8 Apr 24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
5 Apr 24
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
5 Apr 24